miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis

被引:61
作者
Larne, Olivia [1 ]
Hagman, Zandra [1 ]
Lilja, Hans [1 ,2 ,3 ]
Bjartell, Anders [4 ]
Edsjo, Anders [5 ]
Ceder, Yvonne [1 ]
机构
[1] Lund Univ, Div Clin Chem, Dept Lab Med, S-22381 Lund, Sweden
[2] Mem Sloan Kettering Canc Ctr, Dept Surg Urol Clin Labs Epidemiol & Biostat, New York, NY 10021 USA
[3] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England
[4] Lund Univ, Dept Clin Sci, Lund, Sweden
[5] Lund Univ, Ctr Mol Pathol, Lund, Sweden
基金
瑞典研究理事会;
关键词
MICRORNA EXPRESSION; PROTEINS; MUTATION; ANTIGEN; MYC;
D O I
10.1093/carcin/bgv063
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Androgen signalling through the androgen receptor (AR) is essential for prostate cancer initiation, progression and transformation to the lethal castration-resistant state. The aim of this study was to characterize the mechanisms by which miR-145 deregulation contribute to prostate cancer progression. The miR-145 levels, measured by quantitative reverse transcription-polymerase chain reaction, were found to inversely correlate with occurrence of metastases, survival and androgen deprivation therapy response in a well-characterized prostate cancer cohort. Introduction of ectopic miR-145 in prostate cancer cells generated an inhibitory effect on the AR at both transcript and protein levels as well as its activity and downstream targets prostate-specific antigen (PSA), kallikrein-related peptidase 2 and TMPRSS2. The regulation was shown to be mediated by direct binding using Ago2-specific immunoprecipitation, but there was also indication of synergetic AR activation. These findings were verified in clinical prostate specimens by demonstrating inverse correlations between miR-145 and AR expression as well as serum PSA levels. In addition, miR-145 was found to regulate androgen-dependent cell growth in vitro. Our findings put forward novel possibilities of therapeutic intervention, as miR-145 potentially could decrease both the stem cells and the AR expressing bulk of the tumour and hence reduce the transformation to the deadly castration-resistant form of prostate cancer.
引用
收藏
页码:858 / 866
页数:9
相关论文
共 37 条
[1]   Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer [J].
Arndt, Greg M. ;
Dossey, Lesley ;
Cullen, Lara M. ;
Lai, Angela ;
Druker, Riki ;
Eisbacher, Michael ;
Zhang, Chunyan ;
Tran, Nham ;
Fan, Hongtao ;
Retzlaff, Kathy ;
Bittner, Anton ;
Raponi, Mitch .
BMC CANCER, 2009, 9 :374
[2]  
Chen Z, 2010, BEST PRACT RES CLIN, V29, P151
[3]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[4]   The development of androgen-independent prostate cancer [J].
Feldman, BJ ;
Feldman, D .
NATURE REVIEWS CANCER, 2001, 1 (01) :34-45
[5]   Estimates of cancer incidence and mortality in Europe in 2008 [J].
Ferlay, J. ;
Parkin, D. M. ;
Steliarova-Foucher, E. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (04) :765-781
[6]   Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? [J].
Filipowicz, Witold ;
Bhattacharyya, Suvendra N. ;
Sonenberg, Nahum .
NATURE REVIEWS GENETICS, 2008, 9 (02) :102-114
[7]   Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1 [J].
Fuse, Miki ;
Nohata, Nijiro ;
Kojima, Satoko ;
Sakamoto, Shinichi ;
Chiyomaru, Takeshi ;
Kawakami, Kazumori ;
Enokida, Hideki ;
Nakagawa, Masayuki ;
Naya, Yukio ;
Ichikawa, Tomohiko ;
Seki, Naohiko .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38 (04) :1093-1101
[8]   miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients [J].
Hagman, Z. ;
Haflidadottir, B. S. ;
Ceder, J. A. ;
Larne, O. ;
Bjartell, A. ;
Lilja, H. ;
Edsjo, A. ;
Ceder, Y. .
BRITISH JOURNAL OF CANCER, 2013, 108 (08) :1668-1676
[9]   miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions [J].
Hagman, Zandra ;
Larne, Olivia ;
Edsjo, Anders ;
Bjartell, Anders ;
Ehrnstrom, Roy A. ;
Ulmert, David ;
Lilja, Hans ;
Ceder, Yvonne .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2768-2776
[10]   Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer [J].
Hansson, J ;
Bjartell, A ;
Gadaleanu, V ;
Dizeyi, N ;
Abrahamsson, PA .
PROSTATE, 2002, 53 (01) :50-59